523OFOxTROT: An international randomised controlled trial in 1053 patients evaluating neoadjuvant chemotherapy (NAC) for colon cancer. On behalf of the FOxTROT Collaborative Group

ConclusionsSix weeks NAC for operable primary colon cancer can be delivered safely, with improved perioperative morbidity and marked pathological downstaging including some pCRs. There is a trend toward better disease control at 2 years. Subgroup analyses including impact by MMR status and effect of panitumumab will be presented at the meeting.Clinical trial identificationISRCTN 87163246.Legal entity responsible for the studyUniversity of Birmingham.FundingPrimary funder Cancer Research UK; Additional support: Amgen Pharma.DisclosureThe author has declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research